DWP Comprehensive Review
Center for Substance Abuse Prevention
Drug Testing Advisory Board

Lisa S. Davis, MS
DTAB Designated Federal Officer
U.S. Department of Health and Human Services
Substance Abuse and Mental Health Services Administration
Division of Workplace Programs

June 21, 2022
Open Session - Public
Comprehensive Review

Purpose

• Conduct a high-level review of the Federal Drug Testing Program to:
  – Assess critical issues affecting the program now and in the future
  – Review the state of the art and science
  – Identify key policy and technical challenges
  – Highlight best practices
The Working Groups

**Working Group 1: Current Legal, Political, and Social Issues**
Farm Bill, FAST Act, Mandates for Hair Testing

**Working Group 2: The Scientific and Laboratory Issues**
Emerging Drugs, Evolving Technology, Alternate Matrices

**Working Group 3: Managing the Program in 2022 and Beyond**
Telework, Information flow from EAPS, supervisors, employees
Plenary 1 – May 17-18, 2022
- Reviewed the origins and development of the drug testing program
- Surveyed the current legal environment
- Examined drug use trends
- Described current program challenges

Working Groups
- Will meet over the summer to discuss key questions

Desired Outcome
- Summary Report of Issues
- Assess Strengths and Weaknesses of each Area
- Identify Challenges in Science and Policy
- Describe Future Tasks to Address Challenges